Intellia Therapeutics, Inc. (NTLA) is a publicly traded company in the Unknown sector. Across all available filings, 36 corporate insiders have executed 456 transactions totaling $334.5M, demonstrating a bearish sentiment with -$286.3M in net insider flow. The most recent transaction on Jan 5, 2026 involved a sale of 8,508 shares valued at $78.4K.
No significant insider buying has been recorded for NTLA in the recent period.
No significant insider selling has been recorded for NTLA in the recent period.
Based on recent SEC filings, insider sentiment for NTLA is bearish with an Insider Alignment Score of 7/100 and a net flow of -$286.3M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Intellia Therapeutics, Inc. (NTLA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 36 insiders are actively trading NTLA stock, having executed 456 transactions in the past 90 days. The most active insider is Jean Francois Formela (Executive), who has made 52 transactions totaling $155.4M.
Get notified when executives and directors at NTLA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | C. Schultes Birgit | EVP, Chief Scientific Officer | Sale | 8,508 | $9.21 | $78.4K | |
| Jan 5, 2026 | M. Leonard John | Executive | Sale | 34,146 | $9.21 | $314.5K | |
| Dec 12, 2025 | M. Leonard John | Executive | Option Exercise | 8,557 | $6.83 | $58.4K | |
| Dec 11, 2025 | M. Leonard John | Executive | Sale | 49,959 | $9.49 | $474.1K | |
| Dec 11, 2025 | M. Leonard John | Executive | Sale | 32,832 | $9.47 | $310.9K | |
| Dec 11, 2025 | M. Leonard John | Executive | Sale | 5,355 | $9.59 | $51.4K | |
| Dec 11, 2025 | M. Leonard John | Executive | Option Exercise | 49,959 | $6.83 | $341.2K | |
| Oct 1, 2025 | P. Dube Michael | Executive | Sale | 1,871 | $17.38 | $32.5K | |
| Oct 1, 2025 | C. Schultes Birgit | Executive | Sale | 31 | $17.38 | $539 | |
| Aug 20, 2025 | J. Chase William | Executive | Purchase | 100,000 | $10.03 | $1.0M | Large |
| Jul 23, 2025 | J. Dulac Edward III | Executive | Sale | 7,462 | $14.02 | $104.6K | |
| Jul 1, 2025 | Goodman Jesse | Executive | Sale | 1,547 | $9.23 | $14.3K | |
| Jun 30, 2025 | Goodman Jesse | Executive | Sale | 1,547 | $9.56 | $14.8K | |
| Jul 22, 2024 | J. Dulac Edward III | Executive | Award | 66,324 | $N/A | $0 | |
| Jul 1, 2024 | P. Dube Michael | Executive | Award | 17,801 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 258 | $310.4M | 87.2% |
Purchase(P) | 11 | $24.1M | 6.8% |
Exercise(M) | 90 | $20.5M | 5.8% |
Award(A) | 69 | $817.7K | 0.2% |
Other(J) | 5 | $0 | 0.0% |
Conversion(C) | 23 | $0 | 0.0% |
Insider selling pressure at Intellia Therapeutics, Inc. has increased, with 36 insiders executing 456 transactions across all time. Total sales of $310.4M significantly outpace purchases of $24.1M, resulting in a net outflow of $286.3M. This selling activity appears largely discretionary, which may warrant closer attention from investors.